Aims-To compare the nested polymerase chain reaction (PCR) assay for the detection of cytomegalovirus (CMV) DNA in peripheral blood leucocytes and plasma obtained from heparinised blood; to determine the efficiency of various DNA extraction methods to minimise inhibition ofplasma PCR and their effect on the sensitivity of plasma PCR; to determine the inhibitory effect of heparin, dextran, and EDTA on the CMV PCR assay. Methods-217 heparinised blood specimens from 58 bone marrow transplant patients were processed and the sensitivities and specificities of the PCR assays using peripheral blood leucocytes and plasma (with simple, Instagene, and Geneclean extraction methods) were compared to those of conventional CMV culture. In a separate experiment, dilutions of heparin, dextran, and EDTA were included in PCR assays. Results-The detection of CMV DNA using peripheral blood leucocytes for PCR assay was significantly more sensitive (100%) than when using plasma (60%). Instagene and Geneclean extraction removed inherent inhibition but did not improve the sensitivity of the plasma PCR reaction. Heparin had an inhibitory effect on PCR.
Bone marrow transplantation is one of the well recognised methods of treatment for malignant and non-malignant haematological diseases, some solid tumours, and metabolic disorders. Opportunistic infections that occur as a result of severe immunosuppression have always been a major cause of morbidity and mortality in bone marrow transplant patients. The nature of the infection is dependent on the period oftime after bone marrow transplant. ' During the post-engraftment period (day 30 to day 100), human cytomegalovirus (CMV) is one of the most common pathogens in these patients, in whom the most serious manifestation is CMV pneumonitis. Although ganciclovir is recommended as the drug of choice for CMV disease, the decision on to whom it should be given and when has always been difficult because of its myelosuppressive properties. Giving ganciclovir prophylaxis to bone marrow transplant patients who were seropositive for CMV and to seronegative recipients who received bone marrow or blood products from seropositive donors has caused unnecessary bone marrow suppression.2 On the other hand, giving ganciclovir treatment only to those whose leucocyte or broncho-alveolar lavage (BAL) fluid tested positive for CMV by shell vial or conventional cell cultures (requiring at least two or 14 days, respectively) is too late as the disease has progressed to a more advanced stage.3 Hence newer diagnostic methods are required to minimise the overuse of ganciclovir prophylaxis and avoid withholding ganciclovir from those who would benefit from it. The development of rapid diagnostic methods to detect CMV DNA or antigen in plasma or buffy coat5 have facilitated earlier and more specific detection of CMV disease, and allowed the earlier institution of antiviral therapy.
In this longitudinal study two rapid methods, the nested polymerase chain reaction (PCR) assay for the detection of CMV DNA in plasma and peripheral blood leucocytes obtained from heparinised blood, were evaluated. Heparinised blood is frequently used for the detection of CMV DNA in plasma.6 7 However, heparin has been reported to be an inhibitor of PCR.8-' We therefore investigated whether plasma obtained from heparinised blood is a suitable clinical specimen for the detection of CMV DNA by PCR. In addition the effects of another anticoagulant, ethylene diaminetetra-acetic acid (EDTA), and dextran, used in processing blood specimens, on the sensitivity of the PCR assay were studied.
Three DNA extraction methods were also evaluated for their efficiency in removing PCR inhibitors from plasma.
Methods
This study included 217 specimens from 58 patients who underwent bone marrow transplantation in Queen Mary Hospital in Hong Kong (1991-93).
SPECIMEN COLLECTION AND PROCESSING
Ten millilitres of heparinised blood (containing 500 U heparin) were taken weekly from each patient from engraftment (absolute neutrophil count in peripheral blood > 0.5xIO91l) to day 100 after bone marrow transplantation or until the patient died. Plasma and buffy coat were extracted as follows. The blood was mixed with an equal volume of 6% (wt/vol) dextran suspended in phosphate buffered saline (PBS) and was left at 37°C for 30 minutes for sedimentation. The upper cloudy layer was centrifuged at 1500 rpm for 10 minutes and the supernatant fluid (that is the plasma) was stored at -20°C before further processing. The pellet was suspended in hypotonic saline at 4°C for three minutes to lyse residual red blood cells, followed by rinsing in PBS. This last step was repeated and the sedimented peripheral blood leucocytes were harvested.
The plasma and peripheral blood leucocytes were further processed for the nested PCR assay. The plasma was filtered through a 0.45 gm filter and 100 gl of the filtrate was digested with 100 gl of lysing buffer (containing proteinase K at 120 jtg/ml) at 56°C for one hour. The protease was inactivated at 95°C for 10 minutes. An aliquot, specified below, was used for plasma PCR. Peripheral blood leucocytes were resuspended in distilled water at a concentration of 2x106 cells/ml and boiled for 15 The two-tube nested PCR assay was modified from a published protocol." All DNA extracts and controls were denatured at 95°C for 15 minutes and chilled in ice for five minutes. For initial amplification with 0.5 jM external primers (CMTR1 5'-CTGTCGGTATGGT CTCTTC-3', CMTR2 5'-CCCGACACGCG GAAAAGAAA-3') (Applied Biosystems model 380A synthesiser, Applied Biosystems, California, USA), the PCR mixture (100 gl) contained denatured peripheral blood leucocytes or plasma DNA, PCR buffer (10 mM Tris-HCl pH 8.3,50 mM KCl, 3mM MgCl2, and 0.0 1% gelatin), 200 ,uM of each deoxynucleoside triphosphates (dNTPs), and 2.5 U Taq polymerase (Perkin-Elmer Cetus, Norwalk, USA). Each sample was amplified in 30 cycles of 94°C for one minute, 55°C for one minute, and 72°C for one minute, and with a final extension at 72°C for 10 minutes in an automated thermal cycler (Perkin-Elmer Cetus, Gouda, The Netherlands). For subsequent amplification with 0.5 jM internal primers (CMTR3 5'-TCTCTGGTCCTGA TCGTCTT-3', CMTR4 5'-GTGACCTACC AACGTAGGTT-3') (Applied Biosystems model 380A synthesiser), 10 ,ul of the first PCR product was transferred to a new PCR reaction mixture of the same composition and final volume as before. The PCR conditions for denaturation, annealing, and extension, as well as the number of cycles, were as outlined above. Cloned amplicon, a construct with the segment of the morphological transforming region II (mtr II) gene of CMV amplified by CMTR1 and CMTR2 cloned into pUC19 (Boehringer Mannheim, Germany), and distilled water were used as the positive and negative controls, respectively. Procedures for avoiding false positive results were followed strictly.'2 To minimise false negative results due to the presence of inhibitors in the samples, a f globin control was included in parallel with every sample in the leucocyte PCR assay,'3 and a control spiked with 100 copies of CMV DNA accompanied each clinical sample in the plasma PCR assay.
DETECTION AND CONFIRMATION OF AMPLIFIED PRODUCTS
Ten microlitres of each final PCR product were electrophoresed in 2% (wt/vol) agarose gel (Promega, Madison, USA), with a molecular size marker ('DX-1 74 DNA Hae III digest; Promega, Madison, USA) in parallel. Electrophoresis in Tris-borate-EDTA (TBE) buffer was performed at 120 V for one hour. The gel was stained with ethidium bromide (0. 5 jg/ml) for 15 minutes, rinsed, and photographed under ultraviolet light illumination. A 168 bp fragment-located within the morphological transforming region II (mtr II) of the CMV genome was generated in positive samples.'4 (0.15, 0.03, and 0.015% (wt/vol)), and EDTA (0.045 mg/ml) were used to determine the possible inhibitory effect of these substances on the CMV PCR reactions; 1.25 U/ml heparin, 0.15% dextran, and 0.045 mg/ml EDTA corresponded to the final concentrations of these substances in routine plasma PCR experiments using heparinised or EDTA blood samples.
STATISTICS
The results were compared using the x2 test (Sigmastat for Windows 1.0). A p value of < 0.05 was considered statistically significant. The effect of heparin, dextran, and EDTA on the amplification of control CMV DNA by nested PCR is shown in fig 2. Dextran and EDTA did not interfere with the assay. However, heparin was profoundly inhibitory even when diluted to 10-fold its usual concentration in the reaction mix for plasma PCR (0.0 125 U/ml).
Discussion
The development of a rapid, minimally invasive, and highly sensitive method in a routine laboratory for screening bone marrow transplant patients for the presence of CMV disease is crucial in deciding to whom ganciclovir should be given. In our bone marrow transplant patients, detection of CMV DNA using peripheral blood leucocytes obtained from heparinised blood for PCR achieved a sensitivity of 100%, which makes the assay a suitable method for screening CMV disease in bone marrow transplant patients. If the leucocyte CMV PCR assay is negative for a particular patient, one may conclude with confidence that the patient is unlikely to have an active CMV disease. All patients tested positive by this method must be further assessed by other assays for CMV disease (for example, pp65 antigenaemia assay7 or shell vial culture for detection of early antigen expression' 4), as well as looking for clinical signs and symptoms of CMV disease.
Both plasma and leucocytes obtained from peripheral blood anticoagulated with either heparin or EDTA have been used for the detection of CMV DNA by PCR assay in patients with or without bone marrow transplants, but conflicting results have been reported and no conclusion on the most appropriate source of CMV DNA has been reached. 6 7 1623 In one study with bone marrow transplant patients in which plasma obtained from heparinised blood was used, a sensitivity of 100% was reported compared to conventional CMV culture, though the assay was not performed in parallel with a peripheral blood leucocyte PCR assay.6 On the other hand, two studies on bone marrow transplant patients showed that CMV DNA was often detected in leucocytes before the onset of CMV disease, and CMV DNA in plasma samples was usually detected after the onset of CMV disease. 22 23 Nevertheless, neither of these reports mentioned the type of anticoagulant used in their blood samples, nor the possibility of any inhibitor problem. In our study, when heparinised blood was used the sensitivity of the peripheral blood leucocyte PCR assay (100%) was significantly higher than that of the plasma PCR assay (60%).
Heparin, which had a profoundly inhibitory effect on the PCR reactions even at 0.0125 U/ml (fig 2) , is likely to contribute to the relatively low sensitivity and the inhibitor problem in the negative samples of plasma PCR assays. It has been reported that heparin is an exogenous inhibitor to PCR assays in at least three studies.8-" In one study, heparinase was reported to be effective in eliminating the inhibitory effect of heparin, but heparinase treatment must be followed by treatment with Ca"+ (1.3 mM) and glycol-etherdiamine-tetraacetic acid (EGTA, 13.5 mM), but an EGTA concentration of above 5 counting,'0 which would increase the feasibility of PCR assay using leucocytes as a routine diagnostic assay.
In conclusion, detection of CMV DNA by nested PCR using peripheral blood leucocytes is more sensitive than using plasma from heparinised blood in bone marrow transplant recipients. Therefore leucocyte PCR, which can be completed within 10 hours, is a more useful screening test in helping to decide on the group of bone marrow transplant recipients to whom ganciclovir should be given. 
